Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] becomes the Only Facilitated Subcutaneous…